PGGM Investments Purchases 19,823 Shares of argenx SE (NASDAQ:ARGX)

PGGM Investments boosted its position in argenx SE (NASDAQ:ARGX) by 44.5% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 64,409 shares of the company’s stock after purchasing an additional 19,823 shares during the period. PGGM Investments’ holdings in argenx were worth $27,698,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently made changes to their positions in the company. Sequoia Financial Advisors LLC grew its stake in shares of argenx by 3.1% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 1,713 shares of the company’s stock worth $737,000 after acquiring an additional 52 shares during the period. SG Americas Securities LLC boosted its position in argenx by 10.4% during the second quarter. SG Americas Securities LLC now owns 2,999 shares of the company’s stock worth $1,290,000 after purchasing an additional 283 shares during the period. Park Avenue Securities LLC increased its stake in shares of argenx by 7.2% in the second quarter. Park Avenue Securities LLC now owns 1,324 shares of the company’s stock worth $569,000 after purchasing an additional 89 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of argenx by 51.3% in the second quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock worth $51,000 after purchasing an additional 40 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale raised its position in shares of argenx by 1.5% in the first quarter. DekaBank Deutsche Girozentrale now owns 8,445 shares of the company’s stock valued at $3,320,000 after purchasing an additional 128 shares during the period. 60.32% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Piper Sandler raised their price target on argenx from $522.00 to $535.00 and gave the stock an “overweight” rating in a report on Monday, June 24th. Deutsche Bank Aktiengesellschaft upgraded argenx from a “hold” rating to a “buy” rating in a research note on Thursday, July 25th. Bank of America reiterated a “buy” rating and set a $607.00 price target (up from $535.00) on shares of argenx in a research report on Monday, June 24th. Truist Financial raised their price objective on shares of argenx from $480.00 to $540.00 and gave the company a “buy” rating in a research report on Monday, July 22nd. Finally, Wells Fargo & Company upped their target price on shares of argenx from $543.00 to $547.00 and gave the stock an “overweight” rating in a report on Friday, July 26th. Three analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $540.37.

argenx Stock Performance

NASDAQ:ARGX traded down $8.68 during mid-day trading on Wednesday, reaching $522.36. The stock had a trading volume of 534,415 shares, compared to its average volume of 331,640. The stock has a market capitalization of $31.04 billion, a P/E ratio of -92.29 and a beta of 0.64. The firm has a 50 day moving average price of $452.92 and a two-hundred day moving average price of $407.38. argenx SE has a one year low of $327.73 and a one year high of $540.49.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, July 25th. The company reported $0.45 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.89) by $1.34. argenx had a negative net margin of 12.31% and a negative return on equity of 7.33%. The firm had revenue of $489.43 million during the quarter, compared to analyst estimates of $436.66 million. During the same period in the previous year, the business posted ($1.69) EPS. Research analysts forecast that argenx SE will post -0.48 earnings per share for the current year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.